Chemotherapy dosing in overweight and obese patients with cancer

Nature Reviews Clinical Oncology

Volumn 10, Issue 8, 2013, Pages 451-459

  Lyman, Gary H ^a   Sparreboom, Alex ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; THIOTEPA; TOPOTECAN; TROXACITABINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BODY SURFACE; BODY WEIGHT; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; EPIDEMIC; EVIDENCE BASED MEDICINE; HUMAN; LUNG TOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OBESITY; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 84881479689     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.108     Document Type: Review

References (107)

1. Reeves, G. K. et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ 335, 1134 (2007
2. Lyman, G. H., Dale, D. C. & Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J. Clin. Oncol. 21, 4524-4531 (2003
3. Lyman, G. H., Dale, D. C., Friedberg, J., Crawford, J. & Fisher, R. I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J. Clin. Oncol. 22, 4302-4311 (2004
4. Griggs, J. J., Sorbero, M. E. & Lyman, G. H. Undertreatment of obese women receiving breast cancer chemotherapy. Arch. Intern. Med. 165, 1267-1273 (2005
5. Pinkel, D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 18, 853-856 (1958
6. Pai, M. P. Drug dosing based on weight and body surface area: Mathematical assumptions and limitations in obese adults. Pharmacotherapy 32, 856-868 (2012
7. Field, K. M. et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: Results of a nationwide survey. J. Oncol. Pract. 4, 108-113 (2008
8. Hunter, R. J. et al. Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA). Cancer Treat. Rev. 35, 69-78 (2009
9. Lyman, G. H. Impact of chemotherapy dose intensity on cancer patient outcomes. J. Natl Compr. Canc. Netw. 7, 99-108 (2009
10. Frei, E. 3rd & Canellos, G. P. Dose: A critical factor in cancer chemotherapy. Am. J. Med. 69, 585-594 (1980
11. Schabel, F. M. Jr. The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors. Cancer Res. 29, 2384-2389 (1969
12. Skipper, H. E. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28, 1479-1499 (1971
13. Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727-1733 (1979
14. Goldie, J. H. & Coldman, A. J. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res. 44, 3643-3653 (1984
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365, 1687-1717 (2005
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al. Adjuvant chemotherapy in oestrogen receptor poor breast cancer: Patient-level meta-analysis of randomised trials. Lancet 371, 29-40 (2008
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432-444 (2012
18. Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M. & Brambilla, C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N. Engl. J. Med. 332, 901-906 (1995
19. Hryniuk, W. & Levine, M. N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol. 4, 1162-1170 (1986
20. Hanna, R. K. et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol. Oncol. 129, 74-80 (2013
21. Bosly, A. et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B cell lymphoma patients treated with CHOP. Ann. Hematol. 87, 277-283 (2008
22. Kwak, L. W., Halpern, J., Olshen, R. A. & Horning, S. J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J. Clin. Oncol. 8, 963-977 (1990
23. Pettengell, R., Schwenkglenks, M. & Bosly, A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP 21 chemotherapy. Ann. Hematol. 87, 429-430 (2008
24. Di Maio, M. et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non small cell lung cancer: A pooled analysis of three randomised trials. Lancet Oncol. 6, 669-677 (2005
25. Mayers, C., Panzarella, T. & Tannock, I. F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91, 2246-2257 (2001
26. Griggs, J. J. et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J. Clin. Oncol. 25, 2522-2527 (2007
27. Griggs, J. J. et al. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J. Clin. Oncol. 25, 277-284 (2007
28. Shayne, M. et al. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 115, 5319-5328 (2009
29. Weycker, D., Barron, R., Edelsberg, J., Kartashov, A. & Lyman, G. H. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res. Treat. 133, 301-310 (2012
30. Bonneterre, J. et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 23, 2686-2693 (2005
31. Budman, D. R. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group, B. J. Natl Cancer Inst. 90, 1205-1211 (1998
32. Lyman, G. H. et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review. J. Clin. Oncol. 28, 2914-2924 (2010
33. Norton, L. & Simon, R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep. 61, 1307-1317 (1977
34. Norton, L. & Simon, R. Growth curve of an experimental solid tumor following radiotherapy. J. Natl Cancer Inst. 58, 1735-1741 (1977
35. Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003
36. Pfreundschuh, M. et al. Two-weekly or 3 weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL B2 trial of the DSHNHL. Blood 104, 634-641 (2004
37. Pfreundschuh, M. et al. Two-weekly or 3 weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL B1 trial of the DSHNHL. Blood 104, 626-633 (2004
38. DiPaolo, J A., Moore, G. E. & Niedbala, T. F. Experimental studies with actinomycin D. Cancer Res. 17, 1127-1134 (1957
39. Farber, S., Toch, R., Sears, E. & Pinkel, D. Advances in chemotherapy of cancer in man. Adv. Cancer Res. 4, 1-71 (1956
40. Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659-661 (2008
41. Mosteller, R. D. Simplified calculation of body-surface area. N. Engl. J. Med. 317, 1098 (1987
42. Gehan, E. A. & George, S. L. Estimation of human body surface area from height and weight. Cancer Chemother. Rep. 54, 225-235 (1970
43. Haycock, G. B., Schwartz, G. J. & Wisotsky, D. H. Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adults. J. Pediatr. 93, 62-66 (1978
44. Griggs, J. J. et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 30, 1553-1561 (2012
45. Grochow, L. B., Baraldi, C. & Noe, D. Is dose normalization to weight or body surface area useful in adults? J. Natl Cancer Inst. 82, 323-325 (1990
46. Gurney, H. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J. Clin. Oncol. 14, 2590-2611 (1996
47. Reilly, J. J. & Workman, P. Normalisation of anti-cancer drug dosage using body weight and surface area: Is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother. Pharmacol. 32, 411-418 (1993
48. Smorenburg, C. H. et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J. Clin. Oncol. 21, 197-202 (2003
49. Mathijssen, R H. et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: Does it make a difference? Oncologist 12, 913-923 (2007
50. Chatelut, E. et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br. J. Cancer 107, 1100-1106 (2012
51. DeVita, V. T. Jr et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann. Intern. Med. 92, 587-595 (1980
52. Jones, S. E. et al. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: A Southwest Oncology Group study. Cancer 43, 417-425 (1979
53. Hryniuk, W. & Bush, H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 2, 1281-1288 (1984
54. Shayne, M. et al. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res. Treat. 100, 255-262 (2006
55. Shayne, M. et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 110, 1611-1620 (2007
56. Crawford, J. et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: The results of a prospective nationwide study of oncology practice. J. Natl Compr. Canc. Netw. 6, 109-118 (2008
57. Dale, D. C., McCarter, G. C., Crawford, J. & Lyman, G. H. Myelotoxicity and dose intensity of chemotherapy: Reporting practices from randomized clinical trials. J. Natl Compr. Canc. Netw. 1, 440-454 (2003
58. World Health Organization. Obesity and overweight [online], http://www.who.int/mediacentre/factsheets/fs311/en/ (2013
59. Eheman, C. et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118, 2338-2366 (2012
60. Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L. & Brown, M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378, 815-825 (2011
61. Schapira, D. V., Kumar, N. B., Lyman, G. H. & Cox, C. E. Abdominal obesity and breast cancer risk. Ann. Intern. Med. 112, 182-186 (1990
62. Protani, M., Coory, M. & Martin, J. H. Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res. Treat. 123, 627-635 (2010
63. Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 348, 1625-1638 (2003
64. Ewertz, M. et al. Effect of obesity on prognosis after early-stage breast cancer. J. Clin. Oncol. 29, 25-31 (2011
65. Bastarrachea, J., Hortobagyi, G. N., Smith, T. L., Kau, S. W. & Buzdar, A. U. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann. Intern. Med. 120, 18-25 (1994
66. Niraula, S., Ocana, A., Ennis, M. & Goodwin, P. J. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. Breast Cancer Res. Treat. 134, 769-781 (2012
67. Meyerhardt, J. A. et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from Cancer and Leukemia Group B 89803. J. Clin. Oncol. 26, 4109-4115 (2008
68. Protani, M. M., Nagle, C. M. & Webb, P. M. Obesity and ovarian cancer survival: A systematic review and meta-analysis. Cancer Prev. Res. (Phila.) 5, 901-910 (2012
69. Sinicrope, F. A. et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer 119, 1528-1536 (2013
70. Ethier, M. C. et al. Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia. Leuk. Lymphoma 53, 1677-1681 (2012
71. Simkens, L. H. et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur. J. Cancer 47, 2560-2567 (2011
72. Griggs, J. J., Sorbero, M. E., Stark, A. T., Heininger, S. E. & Dick, A. W. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res. Treat. 81, 21-31 (2003
73. Lyman, G. H. Weight-based chemotherapy dosing in obese patients with cancer: Back to the future. J. Oncol. Pract. 8, e62-e64 (2012
74. Thompson, L. A., Lawson, A. P., Sutphin, S. D., Steinke, D. & Adams, V. R. Description of current practices of empiric chemotherapy dose adjustment in obese adult patients. J. Oncol. Pract. 6, 141-145 (2010
75. Georgiadis, M. S., Steinberg, S. M., Hankins, L. A., Ihde, D. C. & Johnson, B. E. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J. Natl Cancer Inst. 87, 361-366 (1995
76. Poikonen, P., Blomqvist, C. & Joensuu, H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol. 40, 67-71 (2001
77. Rosner, G. L. et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from cancer and leukemia group B study 8541. J. Clin. Oncol. 14, 3000-3008 (1996
78. Carroll, J., Protani, M., Walpole, E. & Martin, J. H. Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: A systematic review. Breast Cancer Res. Treat. 136, 323-330 (2012
79. Schwartz, J., Toste, B. & Dizon, D. S. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. Gynecol. Oncol. 114, 53-56 (2009
80. Greenman, C. G., Jagielski, C. H. & Griggs, J. J. Breast cancer adjuvant chemotherapy dosing in obese patients: Dissemination of information from clinical trials to clinical practice. Cancer 112, 2159-2165 (2008
81. Baker, S. D et al. Factors affecting cytochrome P 450 3A activity in cancer patients. Clin. Cancer Res. 10, 8341-8350 (2004
82. Hanley, M. J., Abernethy, D. R. & Greenblatt, D. J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49, 71-87 (2010
83. Ciarimboli, G. et al. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin. Cancer Res. 18, 1101-1108 (2012
84. Green, B. & Duffull, S. B. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br. J. Clin. Pharmacol. 58, 119-133 (2004
85. Han, P. Y., Duffull, S. B., Kirkpatrick, C. M. & Green, B. Dosing in obesity: A simple solution to a big problem. Clin. Pharmacol. Ther. 82, 505-508 (2007
86. Mathijssen, R. H. & Sparreboom, A. Influence of lean body weight on anticancer drug clearance. Clin. Pharmacol. Ther. 8, 23 (2009
87. de Jongh, F. E. et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J. Clin. Oncol. 19, 3733-3739 (2001
88. Rudek, M. A. et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur. J. Cancer 40, 1170-1178 (2004
89. Sparreboom, A. et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J. Clin. Oncol. 25, 4707-4713 (2007
90. Blouin, R. A., Kolpek, J. H. & Mann, H. J. Influence of obesity on drug disposition. Clin. Pharm. 6, 706-714 (1987
91. Gibbs, J. P. et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 93, 4436-4440 (1999
92. Lyman, G. H. Commentary: Chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines. J. Oncol. Pract. 7, 17-18 (2011
93. American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice guideline data supplement. ASCO [online], http://www.asco.org/ sites/www.asco.org/files/wbd-ds-5.8.12.pdf (2012
94. Meyerhardt, J. A. et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98, 484-495 (2003
95. Meyerhardt, J. A. et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from Intergroup Trial 0114. J. Clin. Oncol. 22, 648-657 (2004
96. Barrett, S. V. et al. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann. Oncol. 19, 898-902 (2008
97. Smith, T. J. & Desch, C. E. Neutropenia-wise and pound-foolish: Safe and effective chemotherapy in massively obese patients. South Med. J. 84, 883-885 (1991
98. Okamoto, H., Nagatomo, A., Kunitoh, H., Kunikane, H. & Watanabe, K. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: A comparison of the performance of three formulae. Cancer Chemother. Pharmacol. 42, 307-312 (1998
99. Wang, Y. & Beydoun, M. A. The obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: A systematic review and meta-regression analysis. Epidemiol. Rev. 29, 6-28 (2007
100. Cossrow, N. & Falkner, B. Race/ethnic issues in obesity and obesity-related comorbidities. J. Clin. Endocrinol. Metab. 89, 2590-2594 (2004
101. Liao, Y. et al. REACH 2010 Surveillance for Health Status in Minority Communities - United States, 2001 -2002. MMWR Surveill. Summ. 53, 1-36 (2004
102. Jenkins, P., Elyan, S. & Freeman, S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur. J. Cancer 43, 544-548 (2007
103. Smith, T. J. et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J. Clin. Oncol. 24, 3187-3205 (2006
104. Lyman, G. H. Comparative effectiveness research in oncology: The need for clarity, transparency and vision. Cancer Invest. 27, 593-597 (2009
105. Lyman, G. H. & Levine, M. Comparative effectiveness research in oncology: An overview. J. Clin. Oncol. 30, 4181-4184 (2012
106. De Jonge, M. E., Mathot, R. A., Van Dam, S. M., Beijnen, J. H. & Rodenhuis, S. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother. Pharmacol. 50, 251-255 (2002
107. Sassi, F. Obesity and the economics of prevention: Fit not fat (OECD Publishing, 2010